CTC
NBIX icon

Cetera Trust Company’s Neurocrine Biosciences NBIX Stock Holding History

Cetera Trust Company’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$320K Hold
2,430
– – 0.18% 108
2025
Q4 		$345K Hold
2,430
– – 0.18% 98
2025
Q3 		$341K Hold
2,430
– – 0.19% 94
2025
Q2 		$305K Buy
2,430
+240
+11% +$27.5K 0.18% 104
2025
Q1 		$242K Hold
2,190
– – 0.15% 138
2024
Q4 		$299K Hold
2,190
– – 0.19% 91
2024
Q3 		$252K Hold
2,190
– – 0.15% 133
2024
Q2 		$301K Hold
2,190
– – 0.19% 93
2024
Q1 		$302K Sell
2,190
-125
-5% -$17.1K 0.18% 98
2023
Q4 		$305K Buy
+2,315
New +$266K 0.19% 91

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cetera Trust Company's NBIX Position: Q1 2026 in Review

Cetera Trust Company held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 2,430 shares worth $320K. The position accounts for 0.18% of the portfolio, ranked #108.

Cetera Trust Company first reported a position in NBIX in Q4 2023 and has held it in 10 quarters since. The position peaked at $345K in Q4 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Cetera Trust Company held 2,430 shares of Neurocrine Biosciences worth $320K as of Q1 2026.
  • Cetera Trust Company left its Neurocrine Biosciences share count unchanged in Q1 2026.
  • Neurocrine Biosciences made up 0.18% of Cetera Trust Company's portfolio in Q1 2026, its #108 holding.
  • Cetera Trust Company first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 10 quarters since.
  • Cetera Trust Company's Neurocrine Biosciences position peaked at $345K in Q4 2025.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Cetera Trust Company's 13F filing for Q1 2026, filed 8 May 2026.